NEW YORK (GenomeWeb) – Immunotherapy and companion diagnostic developer Treos Bio said today it has completed an $8 million private investment round.

The new funding will be used to support an early-stage clinical trial of PolyPEPI, a precision immunotherapy vaccine for colorectal cancer. The company expects to begin the trial this year. It plans to use its companion diagnostics to identify patients that could be likely responders to the vaccine.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.